Assessing the role of ADAM10 in Trastuzumab treatment and resistance
<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | |
| स्वरूप: | थीसिस |
| भाषा: | English |
| प्रकाशित: |
2012
|
| विषय: |